To study the effect of nimodipine on acute ischemic stroke of mild or moderate severity.
- Nimodipine (Nimotop®)Drug
Intervention Desc: Calcium channel blocker (L-type calcium channels)
Single-center, double-blind, randomized, placebo-controlled pilot study of 60 patients.
Eight of the 60 randomized patients were excluded because of incorrect diagnosis. For the remaining 52 patients, 24 were allocated to nimodipine (30 mg qid. orally for 14 days) and 28 to placebo.
|Type||Measure||Time Frame||Safety Issue|
|Primary||Mathew scale score at 4 months.|